Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Efficacy and safety of a novel topical agent for gallstone dissolution: 2-methoxy-6-methylpyridine

Fig. 6

Validation of toxicities of each gallstone-dissolving compound in various in vitro and in vivo models. a In vitro cytotoxicity of each solvent in Vero, L929, and CHO-K1 cells. To compare the in vitro toxicities of MTBE and MMP, cell viability assay was performed using Cyto X cell viability assay kit. The viability of Vero, L929, and CHO-K1 cells did not considerably change according to the concentration of MTBE or MMP (0–1000 μM) over 24 h. b [Right] The effect of each solvent on locomotor activity in larval zebrafish. For determining the CNS toxicity of each solvent, we tracked larval zebrafish locomotion after 1 mM MTBE and 1 mM MMP treatment, respectively, over 60 min. The locomotor activity was normalized against DMSO control and presented as a percentage. While MTBE increased the locomotor activity during the first 6 min after treatment, MMP reduced it during the first 6 min after treatment. However, overall, each group did not show any significant difference in the total locomotor activity when compared with DMSO control. [Left] Total locomotor activity during 60 min, demonstrating no significant difference between MTBE and MMP groups. c Survival rate and body weight changes after oral administration of MTBE and MMP in mice. [Left] Compared to the control group, MTBE and MMP groups demonstrated similar survival patterns. [Right] MMP group demonstrated slight reduction in body weight during 7 days, which recovered by 14 days after the treatment. d Determination of tissue toxicities of each solvent on 14 days after oral administration. [Top] PCNA immunohistochemical stains. The mice treated with MMP showed higher expression of PCNA (a proliferation marker) than the mice treated with MTBE (P < 0.05). [Bottom] BAX immunohistochemical stains. The mice treated with MMP showed lesser expression of BAX (an apoptotic marker) than the mice treated with MTBE (P < 0.05). *P < 0.05. BAX, bcl-2-like protein 4; MMP, 2-methoxy-6-methylpyridine; MTBE, methyl tert-butyl ether; PCNA, proliferation cell nuclear antigen

Back to article page